Nervus vagus-stimulation til behandling af behandlingsrefraktær epilepsi

Per Jensen; Ioannis Tsiropoulos

doi:10.61409/V10230638

Nervus vagus-stimulation til behandling af behandlingsrefraktær epilepsi

Translated title of the contribution: Vagus nerve stimulation for the treatment of treatment-refractory epilepsy

Per Jensen, Ioannis Tsiropoulos

Department of Neurology

Abstract

About 40 % of new-onset epilepsy is drug refractory. If epilepsy surgery is not an option or fails, vagal nerve stimulation (VNS) can be considered. VNS efficacy is reported as more than 50 % seizure frequency reduction in 50-56 % of patients. Features in the newer models offer additional treatment optimization possibilities. Side effects include hoarseness, cough, and dyspnoea. Caution is advised for patients with sleep apnoea or lung disease. VNS has specific limitations concerning MRI. This review presents an overview of VNS treatment in Denmark and discusses future challenges.

Translated title of the contribution	Vagus nerve stimulation for the treatment of treatment-refractory epilepsy
Original language	Danish
Article number	V10230638
Journal	Ugeskrift for Laeger
Volume	186
Issue number	23
ISSN	0041-5782
DOIs	https://doi.org/10.61409/V10230638
Publication status	Published - 3 Jun 2024

Access to Document

10.61409/V10230638Licence: CC BY-NC-ND

Cite this

@article{f409a0298cf74d07ad742f183c60c3f9,

title = "Nervus vagus-stimulation til behandling af behandlingsrefrakt{\ae}r epilepsi",

abstract = "About 40 % of new-onset epilepsy is drug refractory. If epilepsy surgery is not an option or fails, vagal nerve stimulation (VNS) can be considered. VNS efficacy is reported as more than 50 % seizure frequency reduction in 50-56 % of patients. Features in the newer models offer additional treatment optimization possibilities. Side effects include hoarseness, cough, and dyspnoea. Caution is advised for patients with sleep apnoea or lung disease. VNS has specific limitations concerning MRI. This review presents an overview of VNS treatment in Denmark and discusses future challenges.",

keywords = "Humans, Vagus Nerve Stimulation/adverse effects, Drug Resistant Epilepsy/therapy",

author = "Per Jensen and Ioannis Tsiropoulos",

note = "Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2024",

month = jun,

day = "3",

doi = "10.61409/V10230638",

language = "Dansk",

volume = "186",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "23",

}

TY - JOUR

T1 - Nervus vagus-stimulation til behandling af behandlingsrefraktær epilepsi

AU - Jensen, Per

AU - Tsiropoulos, Ioannis

N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2024/6/3

Y1 - 2024/6/3

N2 - About 40 % of new-onset epilepsy is drug refractory. If epilepsy surgery is not an option or fails, vagal nerve stimulation (VNS) can be considered. VNS efficacy is reported as more than 50 % seizure frequency reduction in 50-56 % of patients. Features in the newer models offer additional treatment optimization possibilities. Side effects include hoarseness, cough, and dyspnoea. Caution is advised for patients with sleep apnoea or lung disease. VNS has specific limitations concerning MRI. This review presents an overview of VNS treatment in Denmark and discusses future challenges.

AB - About 40 % of new-onset epilepsy is drug refractory. If epilepsy surgery is not an option or fails, vagal nerve stimulation (VNS) can be considered. VNS efficacy is reported as more than 50 % seizure frequency reduction in 50-56 % of patients. Features in the newer models offer additional treatment optimization possibilities. Side effects include hoarseness, cough, and dyspnoea. Caution is advised for patients with sleep apnoea or lung disease. VNS has specific limitations concerning MRI. This review presents an overview of VNS treatment in Denmark and discusses future challenges.

KW - Humans

KW - Vagus Nerve Stimulation/adverse effects

KW - Drug Resistant Epilepsy/therapy

U2 - 10.61409/V10230638

DO - 10.61409/V10230638

M3 - Review

C2 - 38903031

SN - 0041-5782

VL - 186

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 23

M1 - V10230638

ER -

Nervus vagus-stimulation til behandling af behandlingsrefraktær epilepsi

Abstract

Access to Document

Fingerprint

Cite this